Innate immunity in cystic fibrosis lung disease

Journal of Cystic Fibrosis

Volumn 11, Issue 5, 2012, Pages 363-382

  Hartl, D ^a   Gaggar, A ^b,c   Bruscia, E ^d   Hector, A ^a   Marcos, V ^e   Jung, A ^f   Greene, C ^g   McElvaney, G ^g   Mall, M ^h   Doring G ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b and Clinical Center   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MUNICH   (Germany)

^f UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^g BEAUMONT HOSPITAL   (Ireland)

^h UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Bacteria; Chemokines; Cystic fibrosis; Host defense; IL 17; Immunity; Innate immunity; Lung disease; Macrophages; Migration; Neutrophils; Pattern recognition; PGP; Phagocytosis; Pseudomonas; Toll like receptors

Indexed keywords

CHEMOKINE; CYTOKINE; GLYCINE; HIGH MOBILITY GROUP B1 PROTEIN; MYELOID DIFFERENTIATION FACTOR 88; PROLINE;

ADAPTIVE IMMUNITY; CYSTIC FIBROSIS; DENDRITIC CELL; EPITHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; IMMUNOREGULATION; INNATE IMMUNITY; LEUKOCYTE; LUNG FIBROSIS; MACROPHAGE; MONOCYTE; NEUTROPHIL; PATHOGENESIS; PHAGOCYTE; RESPIRATORY EPITHELIUM; RESPIRATORY TRACT INFLAMMATION; REVIEW; T LYMPHOCYTE; TH17 CELL;

ADAPTIVE IMMUNITY; CHEMOKINES; CYSTIC FIBROSIS; FIBROSIS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE SYSTEM; IMMUNITY, INNATE; INFLAMMATION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY SYSTEM; RESPIRATORY TRACT INFECTIONS; TOLL-LIKE RECEPTORS;

EID: 84866182329     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2012.07.003     Document Type: Review

References (286)

1. Pillarisetti N., Williamson E., Linnane B., Skoric B., Robertson C.F., Robinson P., et al. Infection, Inflammation, and Lung Function Decline in Infants with Cystic Fibrosis. Am J Respir Crit Care Med Jul 1 2011, 184(1):75-81.
2. Ratjen F. What's new in CF airway inflammation: an update. Paediatr Respir Rev 2006, 7(Suppl. 1):S70-S72.
3. Ratjen F. Diagnosing and managing infection in CF. Paediatr Respir Rev 2006, 7(Suppl. 1):S151-S153.
4. Sagel S.D., Dowell E.B., Accurso F.J. Bacterial colonization and infection in the CF lung. Methods Mol Med 2002, 70:433-446.
5. Knowles M.R., Boucher R.C. Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest Mar 2002, 109(5):571-577.
6. Mall M.A. Role of cilia, mucus, and airway surface liquid in mucociliary dysfunction: Lessons from mouse models. J Aerosol Med Pulm Drug Deliv Mar 2008, 21(1):13-24.
7. Bals R., Weiner D.J., Wilson J.M. The innate immune system in cystic fibrosis lung disease. J Clin Invest Feb 1999, 103(3):303-307.
8. Koller B., Bals R., Roos D., Korting H.C., Griese M., Hartl D. Innate immune receptors on neutrophils and their role in chronic lung disease. Eur J Clin Invest Jul 2009, 39(7):535-547.
9. Greene C.M., Carroll T.P., Smith S.G.J., Taggart C.C., Devaney J., Griffin S., et al. TLR-induced inflammation in cystic fibrosis and non-cystic fibrosis airway epithelial cells. J Immunol Feb 1 2005, 174(3):1638-1646.
10. Thelin W.R., Kesimer M., Tarran R., Kreda S.M., Grubb B.R., Sheehan J.K., et al. The cystic fibrosis transmembrane conductance regulator is regulated by a direct interaction with the protein phosphatase 2A. J Biol Chem Dec 16 2005, 280(50):41512-41520.
11. Kreda S.M., Mall M., Mengos A., Rochelle L., Yankaskas J., Riordan J.R., et al. Characterization of wild-type and Delta F508 cystic fibrosis transmembrane regulator in human respiratory epithelia. Mol Biol Cell May 2005, 16(5):2154-2167.
12. Anderson M.P., Berger H.A., Rich D.P., Gregory R.J., Smith A.E., Welsh M.J. Nucleoside Triphosphates Are Required to Open the Cftr Chloride Channel. Cell Nov 15 1991, 67(4):775-784.
13. Anderson M.P., Gregory R.J., Thompson S., Souza D.W., Paul S., Mulligan R.C., et al. Demonstration That Cftr Is a Chloride Channel by Alteration of Its Anion Selectivity. Science Jul 12 1991, 253(5016):202-205.
14. Caputo A., Caci E., Ferrera L., Pedemonte N., Barsanti C., Sondo E., et al. TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity. Science Oct 24 2008, 322(5901):590-594.
15. Stutts M.J., Canessa C.M., Olsen J.C., Hamrick M., Cohn J.A., Rossier B.C., et al. Cftr as a Camp-Dependent Regulator of Sodium-Channels. Science Aug 11 1995, 269(5225):847-850.
16. Mall M.A. Role of the amiloride-sensitive epithelial Na+ channel in the pathogenesis and as a therapeutic target for cystic fibrosis lung disease. Exp Physiol Feb 2009, 94(2):171-174.
17. Matsui H., Grubb B.R., Tarran R., Randell S.H., Gatzy J.T., Davis C.W., et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell Dec 23 1998, 95(7):1005-1015.
18. Tarran R., Button B., Boucher R.C. Regulation of normal and cystic fibrosis airway surface liquid volume by phasic shear stress. Annu Rev Physiol 2006, 68:543-561.
19. Zhou Z., Duerr J., Johannesson B., Schubert S.C., Treis D., Harm M., et al. The ENaC-overexpressing mouse as a model of cystic fibrosis lung disease. J Cyst Fibros Jun 2011, 10(Suppl. 2):S172-S182.
20. Wilke M., Buijs-Offerman R.M., Aarbiou J., Colledge W.H., Sheppard D.N., Touqui L., et al. Mouse models of cystic fibrosis: phenotypic analysis and research applications. J Cyst Fibros Jun 2011, 10(Suppl. 2):S152-S171.
21. Davidson D.J., Dorin J.R. The CF mouse: an important tool for studying cystic fibrosis. Expert Rev Mol Med Mar 12 2001, 2001:1-27.
22. Davidson D.J., Rolfe M. Mouse models of cystic fibrosis. Trends Genet Oct 2001, 17(10):S29-S37.
23. Grubb B.R., Boucher R.C. Pathophysiology of gene-targeted mouse models for cystic fibrosis. Physiol Rev Jan 1999, 79(1 Suppl):S193-S214.
24. Mall M., Grubb B.R., Harkema J.R., O'Neal W.K., Boucher R.C. Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice. Nat Med May 2004, 10(5):487-493.
25. Mall M.A., Harkema J.R., Trojanek J.B., Treis D., Livraghi A., Schubert S., et al. Development of chronic bronchitis and emphysema in beta-epithelial Na+ channel-overexpressing mice. Am J Respir Crit Care Med Apr 1 2008, 177(7):730-742.
26. Zhou Z., Treis D., Schubert S.C., Harm M., Schatterny J., Hirtz S., et al. Preventive but not late amiloride therapy reduces morbidity and mortality of lung disease in betaENaC-overexpressing mice. Am J Respir Crit Care Med Dec 15 2008, 178(12):1245-1256.
27. Teichgraber V., Ulrich M., Endlich N., Riethmuller J., Wilker B., De Oliveira-Munding C.C., et al. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat Med Apr 2008, 14(4):382-391.
28. Zhang Y., Li X., Grassme H., Doring G., Gulbins E. Alterations in Ceramide Concentration and pH Determine the Release of Reactive Oxygen Species by Cftr-Deficient Macrophages on Infection. J Immunol May 1 2010, 184(9):5104-5111.
29. Ulrich M., Worlitzsch D., Viglio S., Siegmann N., Iadarola P., Shute J.K., et al. Alveolar inflammation in cystic fibrosis. J Cyst Fibros May 2010, 9(3):217-227.
30. Campana S., Taccetti G., Ravenni N., Masi I., Audino S., Sisi B., et al. Molecular epidemiology of Pseudomonas aeruginosa, Burkholderia cepacia complex and methicillin-resistant Staphylococcus aureus in a cystic fibrosis center. J Cyst Fibros Aug 2004, 3(3):159-163.
31. Doring G., Hoiby N. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros Jun 2004, 3(2):67-91.
32. Chmiel J.F., Berger M., Konstan M.W. The role of inflammation in the pathophysiology of CF lung disease. Clin Rev Allergy Immunol Aug 2002, 23(1):5-27.
33. Davis P.B., Drumm M., Konstan M.W. Cystic fibrosis. Am J Respir Crit Care Med Nov 1996, 154(5):1229-1256.
34. Ratner D., Mueller C. Immune responses in Cystic Fibrosis; are they intrinsically defective?. Am J Respir Cell Mol Biol Mar 2012, 46(6):715-722.
35. Ramsey B.W., Davies J., McElvaney N.G., Tullis E., Bell S.C., Drevinek P., et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med Nov 3 2011, 365(18):1663-1672.
36. Accurso F.J., Rowe S.M., Clancy J.P., Boyle M.P., Dunitz J.M., Durie P.R., et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med Nov 18 2010, 363(21):1991-2003.
37. Hirtz S., Gonska T., Seydewitz H.H., Thomas J., Greiner P., Kuehr J., et al. CFTR Cl- channel function in native human colon correlates with the genotype and phenotype in cystic fibrosis. Gastroenterology Oct 2004, 127(4):1085-1095.
38. Roth E.K., Hirtz S., Duerr J., Wenning D., Eichler I., Seydewitz H.H., et al. The K+ channel opener 1-EBIO potentiates residual function of mutant CFTR in rectal biopsies from cystic fibrosis patients. PLoS One 2011, 6(8):e24445.
39. Moss R.B. Allergic bronchopulmonary aspergillosis and Aspergillus infection in cystic fibrosis. Curr Opin Pulm Med Nov 2010, 16(6):598-603.
40. Chotirmall S.H., O'Donoghue E., Bennett K., Gunaratnam C., O'Neill S.J., McElvaney N.G. Sputum Candida albicans presages FEV(1) decline and hospital-treated exacerbations in cystic fibrosis. Chest Nov 2010, 138(5):1186-1195.
41. Cimon B., Carrere J., Vinatier J.F., Chazalette J.P., Chabasse D., Bouchara J.P. Clinical significance of Scedosporium apiospermum in patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis Jan 2000, 19(1):53-56.
42. Bendiak G.N., Ratjen F. The approach to Pseudomonas aeruginosa in cystic fibrosis. Semin Respir Crit Care Med Oct 2009, 30(5):587-595.
43. Hartl D. Immunological mechanisms behind the cystic fibrosis-ABPA link. Med Mycol 2009, 47:S183-S191.
44. Thursfield R.M., Holden K., Bush A., Adams A., Nicholson A.G. What Is the Significance of Aspergillus Fumigatus in Bal in Children with Cystic Fibrosis. Pediatr Pulmonol 2011, 304-305.
45. Hartl D., Griese M., Kappler M., Zissel G., Reinhardt D., Rebhan C., et al. Pulmonary T(H)2 response in Pseudomonas aeruginosa-infected patients with cystic fibrosis. J Allergy Clin Immunol 2006, 117(1):204-211.
46. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol May 2010, 11(5):373-384.
47. Kawai T., Akira S. Toll-like Receptors and Their Crosstalk with Other Innate Receptors in Infection and Immunity. Immunity May 27 2011, 34(5):637-650.
48. Takeuchi O., Akira S. Pattern Recognition Receptors and Inflammation. Cell Mar 19 2010, 140(6):805-820.
49. Armstrong L., Medford A.R., Uppington K.M., Robertson J., Witherden I.R., Tetley T.D., et al. Expression of functional toll-like receptor-2 and -4 on alveolar epithelial cells. Am J Respir Cell Mol Aug 2004, 31(2):241-245.
50. Droemann D., Goldmann T., Branscheid D., Clark R., Dalhoff K., Zabel P., et al. Toll-like receptor 2 is expressed by alveolar epithelial cells type II and macrophages in the human lung. Histochem Cell Biol Feb 2003, 119(2):103-108.
51. Greene C.M., Branagan P., McElvaney N.G. Toll-like receptors as therapeutic targets in cystic fibrosis. Expert Opin Ther Targets Dec 2008, 12(12):1481-1495.
52. Muir A., Soong G., Sokol S., Reddy B., Gomez M.I., Van Heeckeren A., et al. Toll-like receptors in normal and cystic fibrosis airway epithelial cells. Am J Respir Cell Mol Jun 2004, 30(6):777-783.
53. Latz E., Schoenemeyer A., Visintin A., Fitzgerald K.A., Monks B.G., Knetter C.F., et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol Feb 2004, 5(2):190-198.
54. Platz J., Beisswenger C., Dalpke A., Koczulla R., Pinkenburg O., Vogelmeier C., et al. Microbial DNA induces a host defense reaction of human respiratory epithelial cells. J Immunol Jul 15 2004, 173(2):1219-1223.
55. Greene C.M., Carroll T.P., Smith S.G., Taggart C.C., Devaney J., Griffin S., et al. TLR-induced inflammation in cystic fibrosis and non-cystic fibrosis airway epithelial cells. J Immunol Feb 1 2005, 174(3):1638-1646.
56. Adamo R., Sokol S., Soong G., Gomez M.I., Prince A. Pseudomonas aeruginosa flagella activate airway epithelial cells through asialoGM1 and toll-like receptor 2 as well as toll-like receptor 5. Am J Respir Cell Mol Biol May 2004, 30(5):627-634.
57. Monick M.M., Yarovinsky T.O., Powers L.S., Butler N.S., Carter A.B., Gudmundsson G., et al. Respiratory syncytial virus up-regulates TLR4 and sensitizes airway epithelial cells to endotoxin. J Biol Chem Dec 26 2003, 278(52):53035-53044.
58. Soong G., Reddy B., Sokol S., Adamo R., Prince A. TLR2 is mobilized into an apical lipid raft receptor complex to signal infection in airway epithelial cells. J Clin Invest May 2004, 113(10):1482-1489.
59. Muir A., Soong G., Sokol S., Reddy B., Gomez M.I., Van Heeckeren A., et al. Toll-like receptors in normal and cystic fibrosis airway epithelial cells. Am J Respir Cell Mol Biol Jun 2004, 30(6):777-783.
60. Hauber H.P., Tulic M.K., Tsicopoulos A., Wallaert B., Olivenstein R., Daigneault P., et al. Toll-like receptors 4 and 2 expression in the bronchial mucosa of patients with cystic fibrosis. Can Respir J Jan-Feb 2005, 12(1):13-18.
61. John G., Yildirim A.O., Rubin B.K., Gruenert D.C., Henke M.O. TLR-4-mediated innate immunity is reduced in cystic fibrosis airway cells. Am J Respir Cell Mol Biol 2010, 42(4):424-431.
62. John G., Chillappagari S., Rubin B.K., Gruenert D.C., Henke M.O. Reduced surface toll-like receptor-4 expression and absent interferon-gamma-inducible protein-10 induction in cystic fibrosis airway cells. Exp Lung Res 2011, 37(6):319-326.
63. Cohen T.S., Prince A. Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat Med 2012, 18(4):509-519.
64. Zhang Z., Louboutin J.P., Weiner D.J., Goldberg J.B., Wilson J.M. Human airway epithelial cells sense Pseudomonas aeruginosa infection via recognition of flagellin by Toll-like receptor 5. Infect Immun 2005, 73(11):7151-7160.
65. de C.V.G.M., Le Goffic R., Balloy V., Plotkowski M.C., Chignard M., Si-Tahar M. TLR 5, but neither TLR2 nor TLR4, is involved in lung epithelial cell response to Burkholderia cenocepacia. FEMS Immunol Med Microbiol 2008, 54(1):37-44.
66. Blohmke C.J., Victor R.E., Hirschfeld A.F., Elias I.M., Hancock D.G., Lane C.R., et al. Innate immunity mediated by TLR5 as a novel antiinflammatory target for cystic fibrosis lung disease. J Immunol 2008, 180(11):7764-7773.
67. Blohmke C.J., Park J., Hirschfeld A.F., Victor R.E., Schneiderman J., Stefanowicz D., et al. TLR5 as an anti-inflammatory target and modifier gene in cystic fibrosis. J Immunol 2010, 185(12):7731-7738.
68. Roussel L., Martel G., Berube J., Rousseau S. P. aeruginosa drives CXCL8 synthesis via redundant toll-like receptors and NADPH oxidase in CFTRF508 airway epithelial cells. J Cyst Fibros 2011, 10(2):107-113.
69. Chotirmall S.H., Branagan P., Gunaratnam C., McElvaney N.G. Aspergillus/allergic bronchopulmonary aspergillosis in an Irish cystic fibrosis population: a diagnostically challenging entity. Respir Care 2008, 53(8):1035-1041.
70. Beisswenger C., Hess C., Bals R. Aspergillus fumigatus conidia induce interferon-beta signalling in respiratory epithelial cells. Eur Respir J 2012, 39(2):411-418.
71. Da Silva C.A., Hartl D., Liu W., Lee C.G., Elias J.A. TLR-2 and IL-17A in chitin-induced macrophage activation and acute inflammation. J Immunol 2008, 181(6):4279-4286.
72. Walsh D.E., Greene C.M., Carroll T.P., Taggart C.C., Gallagher P.M., O'Neill S.J., et al. Interleukin-8 up-regulation by neutrophil elastase is mediated by MyD88/IRAK/TRAF-6 in human bronchial epithelium. J Biol Chem 2001, 276(38):35494-35499.
73. Devaney J.M., Greene C.M., Taggart C.C., Carroll T.P., O'Neill S.J., McElvaney N.G. Neutrophil elastase up-regulates interleukin-8 via toll-like receptor 4. FEBS Lett 2003, 544(1-3):129-132.
74. Shao M.X., Nadel J.A. Neutrophil elastase induces MUC5AC mucin production in human airway epithelial cells via a cascade involving protein kinase C, reactive oxygen species, and TNF-alpha-converting enzyme. J Immunol 2005, 175(6):4009-4016.
75. Bergin D.A., Greene C.M., Sterchi E.E., Kenna C., Geraghty P., Belaaouaj A., et al. Activation of the epidermal growth factor receptor (EGFR) by a novel metalloprotease pathway. J Biol Chem 2008, 283(46):31736-31744.
76. Cosgrove S., Chotirmall S.H., Greene C.M., McElvaney N.G. Pulmonary proteases in the cystic fibrosis lung induce interleukin 8 expression from bronchial epithelial cells via a heme/meprin/epidermal growth factor receptor/Toll-like receptor pathway. J Biol Chem 2011, 286(9):7692-7704.
77. Chotirmall S.H., Greene C.M., Oglesby I.K., Thomas W., O'Neill S.J., Harvey B.J., et al. 17Beta-estradiol inhibits IL-8 in cystic fibrosis by up-regulating secretory leucoprotease inhibitor. Am J Respir Crit Care Med 2010, 182(1):62-72.
78. Taggart C.C., Greene C.M., McElvaney N.G., O'Neill S. Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced IkappaBalpha degradation without affecting phosphorylation or ubiquitination. J Biol Chem 2002, 277(37):33648-33653.
79. Greene C.M., McElvaney N.G., O'Neill S.J., Taggart C.C. Secretory leucoprotease inhibitor impairs Toll-like receptor 2- and 4-mediated responses in monocytic cells. Infect Immun 2004, 72(6):3684-3687.
80. Taggart C.C., Cryan S.A., Weldon S., Gibbons A., Greene C.M., Kelly E., et al. Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding. J Exp Med 2005, 202(12):1659-1668.
81. Oglesby I.K., Bray I.M., Chotirmall S.H., Stallings R.L., O'Neill S.J., McElvaney N.G., et al. miR-126 is downregulated in cystic fibrosis airway epithelial cells and regulates TOM1 expression. J Immunol 2010, 184(4):1702-1709.
82. Gerard C., Rollins B.J. Chemokines and disease. Nat Immunol 2001, 2(2):108-115.
83. Moser B., Loetscher P. Lymphocyte traffic control by chemokines. Nat Immunol 2001, 2(2):123-128.
84. Panina-Bordignon P., D'Ambrosio D. Chemokines and their receptors in asthma and chronic obstructive pulmonary disease. Curr Opin Pulm Med 2003, 9(2):104-110.
85. Zemans R.L., Briones N., Campbell M., McClendon J., Young S.K., Suzuki T., et al. Neutrophil transmigration triggers repair of the lung epithelium via beta-catenin signaling. Proc Natl Acad Sci U S A 2011, 108(38):15990-15995.
86. Zemans R.L., Colgan S.P., Downey G.P. Transepithelial migration of neutrophils: mechanisms and implications for acute lung injury. Am J Respir Cell Mol 2009, 40(5):519-535.
87. Downey D.G., Bell S.C., Elborn J.S. Neutrophils in cystic fibrosis. Thorax 2009, 64(1):81-88.
88. Russell K.J., McRedmond J., Mukherji N., Costello C., Keatings V., Linnane S., et al. Neutrophil adhesion molecule surface expression and responsiveness in cystic fibrosis. Am J Respir Crit Care Med 1998, 157(3):756-761.
89. Downey D.G., Brockbank S., Martin S.L., Ennis M., Elborn J.S. The effect of treatment of cystic fibrosis pulmonary exacerbations on airways and systemic inflammation. Pediatr Pulmonol 2007, 42(8):729-735.
90. Tabary O., Corvol H., Boncoeur E., Chadelat K., Fitting C., Cavaillon J.M., et al. Adherence of airway neutrophils and inflammatory response are increased in CF airway epithelial cell-neutrophil interactions. Am J Physiol Lung Cell Mol Physiol 2006, 290(3):L588-L596.
91. Owen C. Chemokine receptors in airway disease: which receptors to target?. Pulm Pharmacol Ther 2001, 14(3):193-202.
92. Yang D., de la Rosa G., Tewary P., Oppenheim J.J. Alarmins link neutrophils and dendritic cells. Trends Immunol 2009, 30(11):531-537.
93. Yang D., Oppenheim J.J. Alarmins and antimicrobial immunity. Med Mycol 2009, 47(Suppl. 1):S146-S153.
94. Sagel S.D., Accurso F.J. Monitoring inflammation in CF. Cytokines. Clin Rev Allergy Immunol 2002, 23(1):41-57.
95. Nichols D., Chmiel J., Berger M. Chronic inflammation in the cystic fibrosis lung: alterations in inter- and intracellular signaling. Clin Rev Allergy Immunol 2008, 34(2):146-162.
96. Elizur A., Cannon C.L., Ferkol T.W. Airway inflammation in cystic fibrosis. Chest 2008, 133(2):489-495.
97. Le J., Vilcek J. Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities. Lab Invest 1987, 56(3):234-248.
98. Yang M., Kumar R.K., Hansbro P.M., Foster P.S. Emerging roles of pulmonary macrophages in driving the development of severe asthma. J Leukoc Biol 2012, 91(4):557-569.
99. Salva P.S., Doyle N.A., Graham L., Eigen H., Doerschuk C.M. TNF-alpha, IL-8, soluble ICAM-1, and neutrophils in sputum of cystic fibrosis patients. Pediatr Pulmonol 1996, 21(1):11-19.
100. Osika E., Cavaillon J.M., Chadelat K., Boule M., Fitting C., Tournier G., et al. Distinct sputum cytokine profiles in cystic fibrosis and other chronic inflammatory airway disease. Eur Respir J 1999, 14(2):339-346.
101. Balfour-Lynn I.M., Klein N.J., Dinwiddie R. Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis. Arch Dis Child 1997, 77(2):124-130.
102. Colombo C., Faelli N., Tirelli A.S., Fortunato F., Biffi A., Claut L., et al. Analysis of inflammatory and immune response biomarkers in sputum and exhaled breath condensate by a multi-parametric biochip array in cystic fibrosis. Int J Immunopathol Pharmacol 2011, 24(2):423-432.
103. Dinarello C.A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011, 117(14):3720-3732.
104. Wilmott R.W., Frenzke M., Kociela V., Peng L. Plasma interleukin-1 alpha and beta, tumor necrosis factor-alpha, and lipopolysaccharide concentrations during pulmonary exacerbations of cystic fibrosis. Pediatr Pulmonol 1994, 18(1):21-27.
105. Greally P., Hussain M.J., Vergani D., Price J.F. Serum interleukin-1 alpha and soluble interleukin-2 receptor concentrations in cystic fibrosis. Arch Dis Child 1993, 68(6):785-787.
106. Wilmott R.W., Kassab J.T., Kilian P.L., Benjamin W.R., Douglas S.D., Wood R.E. Increased levels of interleukin-1 in bronchoalveolar washings from children with bacterial pulmonary infections. Am Rev Respir Dis 1990, 142(2):365-368.
107. Bonfield T.L., Panuska J.R., Konstan M.W., Hilliard K.A., Hilliard J.B., Ghnaim H., et al. Inflammatory Cytokines in Cystic-Fibrosis Lungs. Am J Respir Crit Care Med 1995, 152(6):2111-2118.
108. Douglas T.A., Brennan S., Gard S., Berry L., Gangell C., Stick S.M., et al. Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis. Eur Respir J 2009, 33(2):305-311.
109. Bonfield T.L., Konstan M.W., Burfeind P., Panuska J.R., Hilliard J.B., Berger M. Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis. Am J Respir Cell Mol Biol 1995, 13(3):257-261.
110. Muhlebach M.S., Reed W., Noah T.L. Quantitative cytokine gene expression in CF airway. Pediatr Pulmonol 2004, 37(5):393-399.
111. Buff S.M., Yu H., McCall J.N., Caldwell S.M., Ferkol T.W., Flotte T.R., et al. IL-10 delivery by AAV5 vector attenuates inflammation in mice with Pseudomonas pneumonia. Gene Ther 2010, 17(5):567-576.
112. Sagel S.D. Noninvasive biomarkers of airway inflammation in cystic fibrosis. Curr Opin Pulm Med 2003, 9(6):516-521.
113. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295(19):2275-2285.
114. Charo I.F., Ransohoff R.M. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006, 354(6):610-621.
115. Kunkel S.L., Strieter R.M., Chensue S.W., Basha M., Standiford T., Ham J., et al. Tumor necrosis factor-alpha, interleukin-8 and chemotactic cytokines. Prog Clin Biol Res 1990, 349:433-444.
116. Winkler M. Role of cytokines and other inflammatory mediators. BJOG 2003, 110(Suppl. 20):118-123.
117. Hartl D., Latzin P., Hordijk P., Marcos V., Rudolph C., Woischnik M., et al. Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. Nat Med 2007, 13(12):1423-1430.
118. Mayer-Hamblett N., Aitken M.L., Accurso F.J., Kronmal R.A., Konstan M.W., Burns J.L., et al. Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am J Respir Crit Care Med 2007, 175(8):822-828.
119. Sagel S.D., Kapsner R., Osberg I., Sontag M.K., Accurso F.J. Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction. Am J Respir Crit Care Med 2001, 164(8):1425-1431.
120. Dean T.P., Dai Y., Shute J.K., Church M.K., Warner J.O. Interleukin-8 concentrations are elevated in bronchoalveolar lavage, sputum, and sera of children with cystic fibrosis. Pediatr Res 1993, 34(2):159-161.
121. Karpati F., Hjelte F.L., Wretlind B. TNF-alpha and IL-8 in consecutive sputum samples from cystic fibrosis patients during antibiotic treatment. Scand J Infect Dis 2000, 32(1):75-79.
122. Schmitt-Grohe S., Naujoks C., Bargon J., Wagner T.O., Schubert R., Hippe V., et al. Interleukin-8 in whole blood and clinical status in cystic fibrosis. Cytokine 2005, 29(1):18-23.
123. Mahler D.A., Huang S., Tabrizi M., Bell G.M. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest 2004, 126(3):926-934.
124. Rao S., Wright A.K., Montiero W., Ziegler-Heitbrock L., Grigg J. Monocyte chemoattractant chemokines in cystic fibrosis. J Cyst Fibros 2009, 8(2):97-103.
125. Brennan S., Sly P.D., Gangell C.L., Sturges N., Winfield K., Wikstrom M., et al. Alveolar macrophages and CC chemokines are increased in children with cystic fibrosis. Eur Respir J 2009, 34(3):655-661.
126. Estell K., Braunstein G., Tucker T., Varga K., Collawn J.F., Schwiebert L.M. Plasma membrane CFTR regulates RANTES expression via its C-terminal PDZ-interacting motif. Mol Cell Biol 2003, 23(2):594-606.
127. Schwiebert L.M., Estell K., Propst S.M. Chemokine expression in CF epithelia: implications for the role of CFTR in RANTES expression. Am J Physiol 1999, 276(3):C700-C710. [Research Support, Non-U.S. Gov't].
128. Hafen G.M., Hartl D., Regamey N., Casaulta C., Latzin P. Allergic bronchopulmonary aspergillosis: the hunt for a diagnostic serological marker in cystic fibrosis patients. Expert Rev Mol Diagn 2009, 9(2):157-164.
129. Hartl D., Buckland K.F., Hogaboam C.M. Chemokines in allergic aspergillosis-from animal models to human lung diseases. Inflamm Allergy Drug Targets 2006, 5(4):219-228.
130. Hartl D., Latzin P., Zissel G., Krane M., Krauss-Etschmann S., Griese M. Chemokines indicate allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Am J Respir Crit Care Med 2006, 173(12):1370-1376.
131. Hartl D., Lee C.G., Da Silva C.A., Chupp G.L., Elias J.A. Novel biomarkers in asthma: chemokines and chitinase-like proteins. Curr Opin Allergy Clin Immunol 2009, 9(1):60-66.
132. Latzin P., Hartl D., Regamey N., Frey U., Schoeni M.H., Casaulta C. Comparison of serum markers for allergic bronchopulmonary aspergillosis in cystic fibrosis. Eur Respir J 2008, 31(1):36-42.
133. Djekic U.V., Gaggar A., Weathington N.M. Attacking the multi-tiered proteolytic pathology of COPD: new insights from basic and translational studies. Pharmacol Ther 2009, 121(2):132-146.
134. Rowe S.M., Jackson P.L., Liu G., Hardison M., Livraghi A., Solomon G.M., et al. Potential role of high-mobility group box 1 in cystic fibrosis airway disease. Am J Respir Crit Care Med 2008, 178(8):822-831.
135. Weathington N.M., van Houwelingen A.H., Noerager B.D., Jackson P.L., Kraneveld A.D., Galin F.S., et al. A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation. Nat Med 2006, 12(3):317-323.
136. Gaggar A., Jackson P.L., Noerager B.D., O'Reilly P.J., McQuaid D.B., Rowe S.M., et al. A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation. J Immunol 2008, 180(8):5662-5669.
137. Snelgrove R.J., Jackson P.L., Hardison M.T., Noerager B.D., Kinloch A., Gaggar A., et al. A critical role for LTA4H in limiting chronic pulmonary neutrophilic inflammation. Science 2010, 330(6000):90-94.
138. Bianchi M.E., Manfredi A.A. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev 2007, 220:35-46.
139. Wang H., Bloom O., Zhang M., Vishnubhakat J.M., Ombrellino M., Che J., et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285(5425):248-251.
140. Scaffidi P., Misteli T., Bianchi M.E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418(6894):191-195.
141. Schiraldi M., Raucci A., Munoz L.M., Livoti E., Celona B., Venereau E., et al. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J Exp Med 2012, 209(3):551-563.
142. Gaggar A., Rowe S.M., Matthew H., Blalock J.E. Proline-Glycine-Proline (PGP) and High Mobility Group Box Protein-1 (HMGB1): Potential Mediators of Cystic Fibrosis Airway Inflammation. Open Respir Med J 2010, 4:32-38.
143. Mollinedo F., Borregaard N., Boxer L.A. Novel trends in neutrophil structure, function and development. Immunol Today 1999, 20(12):535-537.
144. Mantovani A., Cassatella M.A., Costantini C., Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol 2011, 11(8):519-531.
145. Painter R.G., Bonvillain R.W., Valentine V.G., Lombard G.A., LaPlace S.G., Nauseef W.M., et al. The role of chloride anion and CFTR in killing of Pseudomonas aeruginosa by normal and CF neutrophils. J Leukoc Biol 2008, 83(6):1345-1353.
146. Painter R.G., Marrero L., Lombard G.A., Valentine V.G., Nauseef W.M., Wang G. CFTR-mediated halide transport in phagosomes of human neutrophils. J Leukoc Biol 2010, 87(5):933-942.
147. Painter R.G., Valentine V.G., Lanson N.A., Leidal K., Zhang Q., Lombard G., et al. CFTR Expression in human neutrophils and the phagolysosomal chlorination defect in cystic fibrosis. Biochemistry (US) 2006, 45(34):10260-10269.
148. Taggart C., Coakley R.J., Greally P., Canny G., O'Neill S.J., McElvaney N.G. Increased elastase release by CF neutrophils is mediated by tumor necrosis factor-alpha and interleukin-8. Am J Physiol Lung Cell Mol Physiol 2000, 278(1):L33-L41.
149. Brennan S., Cooper D., Sly P.D. Directed neutrophil migration to IL-8 is increased in cystic fibrosis: a study of the effect of erythromycin. Thorax 2001, 56(1):62-64.
150. Alexis N.E., Muhlebach M.S., Peden D.B., Noah T.L. Attenuation of host defense function of lung phagocytes in young cystic fibrosis patients. J Cyst Fibros 2006, 5(1):17-25.
151. Kingma P.S., Dimitriou S., Wooldridge J.L., Karp C.L. Cftr and Neutrophil Function: Our Children May Have the Answers. Pediatr Pulmonol 2010, 138-139.
152. McKeon D.J., Cadwallader K.A., Idris S., Cowburn A.S., Pasteur M.C., Barker H., et al. Cystic fibrosis neutrophils have normal intrinsic reactive oxygen species generation. Eur Respir J 2010, 35(6):1264-1272.
153. Mackarel A.J., Plant B.J., FitzGerald M.X., O'Connor C.M. Cystic fibrosis sputum stimulates CD18-independent neutrophil migration across endothelial cells. Exp Lung Res 2005, 31(4):377-390.
154. McKeon D.J., Condliffe A.M., Cowburn A.S., Cadwallader K.C., Farahi N., Bilton D., et al. Prolonged survival of neutrophils from patients with Delta F508 CFTR mutations. Thorax 2008, 63(7):660-661.
155. McKeon D.J., Cadwallader K.A., Condliffe A.M., Bilton D., Chilvers E.R. The function and fate of neutrophils in cystic fibrosis. Thorax 2005, 60:Ii93-Ii94.
156. Moriceau S., Kantari C., Mocek J., Davezac N., Gabillet J., Guerrera I.C., et al. Coronin-1 is associated with neutrophil survival and is cleaved during apoptosis: potential implication in neutrophils from cystic fibrosis patients. J Immunol 2009, 182(11):7254-7263.
157. Moriceau S., Lenoir G., Witko-Sarsat V. In cystic fibrosis homozygotes and heterozygotes, neutrophil apoptosis is delayed and modulated by diamide or roscovitine: evidence for an innate neutrophil disturbance. J Innate Immun 2010, 2(3):260-266.
158. Gaggar A., Hector A., Bratcher P.E., Mall M.A., Griese M., Hartl D. The role of matrix metalloproteinases in cystic fibrosis lung disease. Eur Respir J 2011, 38(3):721-727.
159. Gaggar A., Li Y., Weathington N., Winkler M., Kong M., Jackson P., et al. Matrix metalloprotease-9 dysregulation in lower airway secretions of cystic fibrosis patients. Am J Physiol Lung Cell Mol Physiol 2007, 293(1):L96-L104.
160. Hector A., Kormann M.S.D., Mack I., Latzin P., Casaulta C., Kieninger E., et al. The Chitinase-Like Protein YKL-40 Modulates Cystic Fibrosis Lung Disease. PLoS One 2011, 6(9).
161. Hilliard J.B., Konstan M.W., Davis P.B. Inflammatory mediators in CF patients. Methods Mol Med 2002, 70:409-431.
162. McAllister F., Henry A., Kreindler J.L., Dubin P.J., Ulrich L., Steele C., et al. Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene-alpha and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosis. J Immunol 2005, 175(1):404-412.
163. Sagel S.D., Kapsner R.K., Osberg I. Induced sputum matrix metalloproteinase-9 correlates with lung function and airway inflammation in children with cystic fibrosis. Pediatr Pulmonol 2005, 39(3):224-232.
164. Sagel S.D., Sontag M.K., Accurso F.J. Relationship Between Antimicrobial Proteins and Airway Inflammation and Infection in Cystic Fibrosis. Pediatr Pulmonol 2009, 44(4):402-409.
165. Sagel S.D., Sontag M.K., Wagener J.S., Kapsner R.K., Osberg L., Accurso F.J. Induced sputum inflammatory measures correlate with lung function in children with cystic fibrosis. J Pediatr 2002, 141(6):811-817.
166. Gray R.D., Imrie M., Boyd A.C., Innes J.A., Porteous D., Greening A.P. Development of sputum calprotectin as a biomarker of cystic fibrosis lung disease activity: Evidence from cross sectional and longitudinal studies. Thorax 2006, (61):Ii34-Ii35.
167. Golden B.E., Clohessy P.A., Russell G., Fagerhol M.K. Calprotectin as a marker of inflammation in cystic fibrosis. Arch Dis Child 1996, 74(2):136-139.
168. Ratjen F., Hartog C.M., Paul K., Wermelt J., Braun J. Matrix metalloproteases in BAL fluid of patients with cystic fibrosis and their modulation by treatment with dornase alpha. Thorax 2002, 57(11):930-934.
169. Thomson E., Brennan S., Senthilmohan R., Gangell C.L., Chapman A.L., Sly P.D., et al. Identifying peroxidases and their oxidants in the early pathology of cystic fibrosis. Free Radic Biol Med 2010, 49(9):1354-1360.
170. Just J., Moog-Lutz C., Houzel-Charavel A., Canteloup S., Grimfeld A., Witko-Sarsat V., et al. Proteinase 3 mRNA expression is induced in monocytes but not in neutrophils of patients with cystic fibrosis. FEBS Lett 1999, 457(3):437-440.
171. Witko-Sarsat V., Halbwachs-Mecarelli L., Schuster A., Nusbaum P., Ueki I., Canteloup S., et al. Proteinase 3, a potent secretagogue in airways, is present in cystic fibrosis sputum. Am J Respir Cell Mol 1999, 20(4):729-736.
172. Adib-Conquy M., Pedron T., Petit-Bertron A.F., Tabary O., Corvol H., Jacquot J., et al. Neutrophils in cystic fibrosis display a distinct gene expression pattern. Mol Med 2008, 14(1-2):36-44.
173. McNally P.G., Doyle M., Taggart C., O'Neill S., Elnazir B., Greene C., et al. Protease anti-protease balance and innate defence proteins levels in the lungs of children with cystic fibrosis: Relationship to P. aeruginosa colonisation status. Pediatr Pulmonol 2007, 262-263.
174. Taggart C.C., Greene C.M., Carroll T.P., O'Neill S.J., McElvaney N.G. Elastolytic proteases: inflammation resolution and dysregulation in chronic infective lung disease. Am J Respir Crit Care Med 2005, 171(10):1070-1076.
175. Moraes T.J., Plumb J., Martin R., Vachon E., Cherepanov V., Koh A., et al. Abnormalities in the pulmonary innate immune system in cystic fibrosis. Am J Respir Cell Mol 2006, 34(3):364-374.
176. Hager M., Cowland J.B., Borregaard N. Neutrophil granules in health and disease. J Intern Med 2010, 268(1):25-34.
177. Downey D.G., Martin S.L., Dempster M., Moore J.E., Keogan M.T., Starcher B., et al. The relationship of clinical and inflammatory markers to outcome in stable patients with cystic fibrosis. Pediatr Pulmonol 2007, 42(3):216-220.
178. Reeves E.P., Bergin D.A., Fitzgerald S., Hayes E., Keenan J., Henry M., et al. A novel neutrophil derived inflammatory biomarker of pulmonary exacerbation in cystic fibrosis. J Cyst Fibros 2011, 11(2):100-107.
179. Voglis S., Quinn K., Tullis E., Liu M., Henriques M., Zubrinich C., et al. Human neutrophil peptides and phagocytic deficiency in bronchiectatic lungs. Am J Respir Crit Care Med 2009, 180(2):159-166.
180. Singh P.K., Schaefer A.L., Parsek M.R., Moninger T.O., Welsh M.J., Greenberg E.P. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 2000, 407(6805):762-764.
181. Parks Q.M., Young R.L., Poch K.R., Malcolm K.C., Vasil M.L., Nick J.A. Neutrophil enhancement of Pseudomonas aeruginosa biofilm development: human F-actin and DNA as targets for therapy. J Med Microbiol 2009, 58(Pt 4):492-502.
182. Jesaitis A.J., Franklin M.J., Berglund D., Sasaki M., Lord C.I., Bleazard J.B., et al. Compromised host defense on Pseudomonas aeruginosa biofilms: characterization of neutrophil and biofilm interactions. J Immunol 2003, 171(8):4329-4339.
183. Kharazmi A., Rechnitzer C., Schiotz P.O., Jensen T., Baek L., Hoiby N. Priming of neutrophils for enhanced oxidative burst by sputum from cystic fibrosis patients with Pseudomonas aeruginosa infection. Eur J Clin Invest 1987, 17(3):256-261.
184. Kolpen M., Hansen C.R., Bjarnsholt T., Moser C., Christensen L.D., van Gennip M., et al. Polymorphonuclear leucocytes consume oxygen in sputum from chronic Pseudomonas aeruginosa pneumonia in cystic fibrosis. Thorax 2010, 65(1):57-62.
185. Koller B., Kappler M., Latzin P., Gaggar A., Schreiner M., Takyar S., et al. TLR expression on neutrophils at the pulmonary site of infection: TLR1/TLR2-mediated up-regulation of TLR5 expression in cystic fibrosis lung disease. J Immunol 2008, 181(4):2753-2763.
186. Usher L.R., Lawson R.A., Geary I., Taylor C.J., Bingle C.D., Taylor G.W., et al. Induction of neutrophil apoptosis by the Pseudomonas aeruginosa exotoxin pyocyanin: a potential mechanism of persistent infection. J Immunol 2002, 168(4):1861-1868.
187. Young R.L., Malcolm K.C., Kret J.E., Caceres S.M., Poch K.R., Nichols D.P., et al. Neutrophil Extracellular Trap (NET)-Mediated Killing of Pseudomonas aeruginosa: Evidence of Acquired Resistance within the CF Airway, Independent of CFTR. PLoS One 2011, 6(9).
188. Dacheux D., Toussaint B., Richard M., Brochier G., Croize J., Attree I. Pseudomonas aeruginosa cystic fibrosis isolates induce rapid, type III secretion-dependent, but ExoU-independent, oncosis of macrophages and polymorphonuclear neutrophils. Infect Immun 2000, 68(5):2916-2924.
189. Worlitzsch D., Herberth G., Ulrich M., Doring G. Catalase, myeloperoxidase and hydrogen peroxide in cystic fibrosis. Eur Respir J 1998, 11(2):377-383. [Research Support, Non-U.S. Gov't].
190. Reynolds W.F., Sermet-Gaudelus I., Gausson V., Feuillet M.N., Bonnefont J.P., Lenoir G., et al. Myeloperoxidase promoter polymorphism -463G is associated with more severe clinical expression of cystic fibrosis pulmonary disease. Mediators Inflamm 2006, 2006(2):36735.
191. Witko-Sarsat V., Allen R.C., Paulais M., Nguyen A.T., Bessou G., Lenoir G., et al. Disturbed myeloperoxidase-dependent activity of neutrophils in cystic fibrosis homozygotes and heterozygotes, and its correction by amiloride. J Immunol 1996, 157(6):2728-2735.
192. van der Vliet A., Cross C.E. Phagocyte oxidants and nitric oxide in cystic fibrosis: new therapeutic targets?. Curr Opin Pulm Med 2000, 6(6):533-539.
193. van der Vliet A., Eiserich J.P., Marelich G.P., Halliwell B., Cross C.E. Oxidative stress in cystic fibrosis: does it occur and does it matter?. Adv Pharmacol 1997, 38:491-513.
194. Tirouvanziam R. Neutrophilic inflammation as a major determinant in the progression of cystic fibrosis. Drug News Perspect 2006, 19(10):609-614.
195. Hayes E., Pohl K., McElvaney N.G., Reeves E.P. The Cystic Fibrosis Neutrophil: A Specialized Yet Potentially Defective Cell. Arch Immunol Ther Exp 2011, 59(2):97-112.
196. Downey G.P. Is There a Primary Neutrophil Defect in Cf?. Pediatr Pulmonol 2011, 163-164.
197. Hector A., Jonas F., Kappler M., Feilcke M., Hartl D., Griese M. Novel Method to Process Cystic Fibrosis Sputum for Determination of Oxidative State. Respiration 2010, 80(5):393-400.
198. Tirouvanziam R., Gernez Y., Conrad C.K., Moss R.B., Schrijver I., Dunn C.E., et al. Profound functional and signaling changes in viable inflammatory neutrophils homing to cystic fibrosis airways. Proc Natl Acad Sci U S A 2008, 105(11):4335-4339.
199. Makam M., Diaz D., Laval J., Gernez Y., Conrad C.K., Dunn C.E., et al. Activation of critical, host-induced, metabolic and stress pathways marks neutrophil entry into cystic fibrosis lungs. Proc Natl Acad Sci U S A 2009, 106(14):5779-5783.
200. Hartl D., Krauss-Etschmann S., Koller B., Hordijk P.L., Kuijpers T.W., Hoffmann F., et al. Infiltrated neutrophils acquire novel chemokine receptor expression and chemokine responsiveness in chronic inflammatory lung diseases. J Immunol 2008, 181(11):8053-8067.
201. Witko-Sarsat V., Sermet-Gaudelus I., Lenoir G., Descamps-Latscha B. Inflammation and CFTR: might neutrophils be the key in cystic fibrosis?. Mediators Inflamm 1999, 8(1):7-11.
202. Brinkmann V., Reichard U., Goosmann C., Fauler B., Uhlemann Y., Weiss D.S., et al. Neutrophil extracellular traps kill bacteria. Science 2004, 303(5663):1532-1535.
203. Amulic B., Cazalet C., Hayes G.L., Metzler K.D., Zychlinsky A. Neutrophil function: from mechanisms to disease. Annu Rev Immunol 2012, 30:459-489.
204. Papayannopoulos V., Zychlinsky A. NETs: a new strategy for using old weapons. Trends Immunol 2009, 30(11):513-521.
205. Manzenreiter R., Kienberger F., Marcos V., Schilcher K., Krautgartner W.D., Obermayer A., et al. Ultrastructural characterization of cystic fibrosis sputum using atomic force and scanning electron microscopy. J Cyst Fibros 2012, 11(2):84-92.
206. Tolker-Nielsen T., Hoiby N. Extracellular DNA and F-actin as targets in antibiofilm cystic fibrosis therapy. Future Microbiol 2009, 4(6):645-647.
207. Ratjen F., Paul K., van Koningsbruggen S., Breitenstein S., Rietschel E., Nikolaizik W. DNA concentrations in BAL fluid of cystic fibrosis patients with early lung disease: influence of treatment with dornase alpha. Pediatr Pulmonol 2005, 39(1):1-4.
208. Perks B., Shute J.K. DNA and actin bind and inhibit interleukin-8 function in cystic fibrosis sputa: in vitro effects of mucolytics. Am J Respir Crit Care Med 2000, 162(5):1767-1772.
209. Kirchner K.K., Wagener J.S., Khan T.Z., Copenhaver S.C., Accurso F.J. Increased DNA levels in bronchoalveolar lavage fluid obtained from infants with cystic fibrosis. Am J Respir Crit Care Med 1996, 154(5):1426-1429.
210. Young R.L., Malcolm K.C., Kret J.E., Poch K.R., Nichols D., Saavedra M.T., et al. Effective Pseudomonas Aeruginosa-Induced Neutrophil Extracellular Trap Response by Normal & Cystic Fibrosis Neutrophils. Pediatr Pulmonol 2010, 281-282.
211. McCormick A., Heesemann L., Wagener J., Marcos V., Hartl D., Loeffler J., et al. NETs formed by human neutrophils inhibit growth of the pathogenic mold Aspergillus fumigatus. Microbes Infect 2010, 12(12-13):928-936.
212. Bonvillain R.W., Painter R.G., Adams D.E., Viswanathan A., Lanson N.A., Wang G. RNA interference against CFTR affects HL60-derived neutrophil microbicidal function. Free Radic Biol Med 2010, 49(12):1872-1880.
213. Phennicie R.T., Sullivan M.J., Singer J.T., Yoder J.A., Kim C.H. Specific resistance to Pseudomonas aeruginosa infection in zebrafish is mediated by the cystic fibrosis transmembrane conductance regulator. Infect Immun 2010, 78(11):4542-4550.
214. Su X., Looney M.R., Su H.E., Lee J.W., Song Y., Matthay M.A. Role of CFTR expressed by neutrophils in modulating acute lung inflammation and injury in mice. Inflamm Res 2011, 60(7):619-632.
215. Pillay J., den Braber I., Vrisekoop N., Kwast L.M., de Boer R.J., Borghans J.A.M., et al. The in vivo half-life of human neutrophils Response. Blood 2011, 117(22):6053-6054.
216. Legssyer R., Huaux F., Lebacq J., Delos M., Marbaix E., Lebecque P., et al. Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice. Respir Res 2006, 7:134.
217. Bruscia E.M., Zhang P.X., Ferreira E., Caputo C., Emerson J.W., Tuck D., et al. Macrophages directly contribute to the exaggerated inflammatory response in cystic fibrosis transmembrane conductance regulator-/- mice. Am J Respir Cell Mol 2009, 40(3):295-304.
218. Mantovani A., Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010, 22(2):231-237.
219. del Fresno C., Garcia-Rio F., Gomez-Pina V., Soares-Schanoski A., Fernandez-Ruiz I., Jurado T., et al. Potent phagocytic activity with impaired antigen presentation identifying lipopolysaccharide-tolerant human monocytes: demonstration in isolated monocytes from cystic fibrosis patients. J Immunol 2009, 182(10):6494-6507.
220. Murphy B.S., Bush H.M., Sundareshan V., Davis C., Hagadone J., Cory T.J., et al. Characterization of macrophage activation states in patients with cystic fibrosis. J Cyst Fibros 2010, 9(5):314-322.
221. Krysko O., Van Zele T., Claeys S., Bachert C. Comment on "potent phagocytic activity with impaired antigen presentation identifying lipopolysaccharide-tolerant human monocytes: demonstration in isolated monocytes from cystic fibrosis patients". J Immunol 2009, 183(8):4831.
222. Meyer M., Huaux F., Gavilanes X., van den Brule S., Lebecque P., Lo Re S., et al. Azithromycin Reduces Exaggerated Cytokine Production by M1 Alveolar Macrophages in Cystic Fibrosis. Am J Respir Cell Mol 2009, 41(5):590-602.
223. Bonfield T.L., Hodges C.A., Drumm M.L. The epithelial cell contingency: myeloid cells and inflammation resolution. Pediatr Pulmonol 2011, 33(33):272.
224. Oceandy D., McMorran B.J., Smith S.N., Schreiber R., Kunzelmann K., Alton E.W.F.W., et al. Gene complementation of airway epithelium in the cystic fibrosis mouse is necessary and sufficient to correct the pathogen clearance and inflammatory abnormalities. Hum Mol Genet 2002, 11(9):1059-1067.
225. Stoltz D.A., Meyerholz D.K., Pezzulo A.A., Ramachandran S., Rogan M.P., Davis G.J., et al. Cystic Fibrosis Pigs Develop Lung Disease and Exhibit Defective Bacterial Eradication at Birth. Sci Transl Med 2010, 2(29).
226. Abdulrahman B.A., Abu Khweek A., Akhter A., Caution K., Kotrange S., Abdelaziz D.H.A., et al. Autophagy stimulation by rapamycin suppresses lung inflammation and infection by Burkholderia cenocepacia in a model of cystic fibrosis. Autophagy 2011, 7(11):1359-1370.
227. Deriy L.V., Gomez E.A., Zhang G.P., Beacham D.W., Hopson J.A., Gallan A.J., et al. Disease-causing Mutations in the Cystic Fibrosis Transmembrane Conductance Regulator Determine the Functional Responses of Alveolar Macrophages. J Biol Chem 2009, 284(51):35926-35938.
228. Di A., Brown M.E., Deriy L.V., Li C., Szeto F.L., Chen Y., et al. CFTR regulates phagosome acidification in macrophages and alters bactericidal activity. Nat Cell Biol 2006, 8(9):933-944.
229. Radtke A.L., Anderson K.L., Davis M.J., DiMagno M.J., Swanson J.A., O'Riordan M.X. Listeria monocytogenes exploits cystic fibrosis transmembrane conductance regulator (CFTR) to escape the phagosome. Proc Natl Acad Sci U S A 2011, 108(4):1633-1638.
230. Del Porto P., Cifani N., Guarnieri S., Di Domenico E.G., Mariggio M.A., Spadaro F., et al. Dysfunctional CFTR alters the bactericidal activity of human macrophages against Pseudomonas aeruginosa. PLoS One 2011, 6(5):19970-19978.
231. Zaman M.M., Gelrud A., Junaidi O., Regan M.M., Warny M., Shea J.C., et al. Interleukin 8 secretion from monocytes of subjects heterozygous for the deltaF508 cystic fibrosis transmembrane conductance regulator gene mutation is altered. Clin Diagn Lab Immunol 2004, 11(5):819-824.
232. Bruscia E.M., Zhang P.X., Satoh A., Caputo C., Medzhitov R., Shenoy A., et al. Abnormal trafficking and degradation of TLR4 underlie the elevated inflammatory response in cystic fibrosis. J Immunol 2011, 186(12):6990-6998.
233. Thomas G.R., Costelloe E.A., Lunn D.P., Stacey K.J., Delaney S.J., Passey R., et al. G551D cystic fibrosis mice exhibit abnormal regulation of inflammation in lungs and macrophages. J Immunol 2000, 164(7):3870-3877.
234. Andersson C., Zaman M.M., Jones A.B., Freedman S.D. Alterations in immune response and PPAR/LXR regulation in cystic fibrosis macrophages. J Cyst Fibros 2008, 7(1):68-78.
235. Yoshimura K., Nakamura H., Trapnell B.C., Chu C.S., Dalemans W., Pavirani A., et al. Expression of the Cystic-Fibrosis Transmembrane Conductance Regulator Gene in Cells of Nonepithelial Origin. Nucleic Acids Res 1991, 19(19):5417-5423.
236. Sorio C., Buffelli M., Angiari C., Ettorre M., Johansson J., Vezzalini M., et al. Defective CFTR Expression and Function Are Detectable in Blood Monocytes: Development of a New Blood Test for Cystic Fibrosis. PLoS One 2011, 6(7).
237. Haggie P.M., Verkman A.S. Cystic fibrosis transmembrane conductance regulator-independent phagosomal acidification in macrophages. J Biol Chem 2007, 282(43):31422-31428.
238. Haggie P.M. Does the Ph of Intracellular Organelles Differ in Cf Cells?. Pediatr Pulmonol 2009, 117-118.
239. Barriere H., Bagdany M., Bossard F., Okiyoneda T., Wojewodka G., Gruenert D., et al. Revisiting the Role of Cftr and Counterion Permeability in the Ph Regulation of Endolysosomes and Phagosomes. Pediatr Pulmonol 2009, 221-222.
240. del Campo R., Martinez E., del Fresno C., Alenda R., Gomez-Pina V., Fernandez-Ruiz I., et al. Translocated LPS might cause endotoxin tolerance in circulating monocytes of Cystic Fibrosis patients. PLoS One 2011, 6(12):29577-29587.
241. del Fresno C., Gomez-Pina V., Lores V., Soares-Schanoski A., Fernandez-Ruiz I., Rojo B., et al. Monocytes from cystic fibrosis patients are locked in an LPS tolerance state: down-regulation of TREM-1 as putative underlying mechanism. PLoS One 2008, 3(7):2667-2675.
242. Srivastava M., Jung S., Wilhelm J., Fink L., Buhling F., Welte T., et al. The inflammatory versus constitutive trafficking of mononuclear phagocytes into the alveolar space of mice is associated with drastic changes in their gene expression profiles. J Immunol 2005, 175(3):1884-1893.
243. Vandivier R.W., Henson P.M., Douglas I.S. Burying the dead: the impact of failed apoptotic cell removal (efferocytosis) on chronic inflammatory lung disease. Chest 2006, 129(6):1673-1682.
244. Watt A.P., Courtney J., Moore J., Ennis M., Elborn J.S. Neutrophil cell death, activation and bacterial infection in cystic fibrosis. Thorax 2005, 60(8):659-664.
245. Vandivier R.W., Richens T.R., Horstmann S.A., deCathelineau A.M., Ghosh M., Reynolds S.D., et al. Dysfunctional cystic fibrosis transmembrane conductance regulator inhibits phagocytosis of apoptotic cells with proinflammatory consequences. Am J Physiol Lung Cell Mol Physiol 2009, 297(4):L677-L686.
246. Vandivier R.W., Fadok V.A., Ogden C.A., Hoffmann P.R., Brain J.D., Accurso F.J., et al. Impaired clearance of apoptotic cells from cystic fibrosis airways. Chest 2002, 121(3 Suppl):89S.
247. Vandivier R.W., Fadok V.A., Hoffmann P.R., Bratton D.L., Penvari C., Brown K.K., et al. Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis. J Clin Invest 2002, 109(5):661-670.
248. Xu Y.Q., Tertilt C., Krause A., Quadri L.E.N., Crystal R.G., Worgall S. Influence of the cystic fibrosis transmembrane conductance regulator on expression of lipid metabolism-related genes in dendritic cells. Respir Res 2009, 3:10.
249. Xu Y., Krause A., Wu W., Joh J., Limberis M.P., Stefan W. Characterization of Pulmonary Dendritic Cells in the Lungs of Cystic Fibrosis Mice Following Pseudomonas Aeruginosa Infection. Pediatr Pulmonol 2009, 255-256.
250. Roghanian A., Drost E.M., MacNee W., Howie S.E.M., Sallenave J.M. Inflammatory lung secretions inhibit dendritic cell maturation and function via neutrophil elastase. Am J Respir Crit Care Med 2006, 174(11):1189-1198.
251. Regamey N, Tsartsali L, Hilliard TN, Fuchs O, Tan HL, Zhu J, et al. Distinct patterns of inflammation in the airway lumen and bronchial mucosa of children with cystic fibrosis. Thorax Feb;67(2):164-170.
252. Schuster M., Tschernig T., Krug N., Pabst R. Lymphocytes migrate from the blood into the bronchoalveolar lavage and lung parenchyma in the asthma model of the brown Norway rat. Am J Respir Crit Care Med 2000, 161(2):558-566.
253. Tschernig T., Boeke K., Steinhoff G., Wonigeit K., Pabst R., Westermann J. The lung as a source and a target organ for T- and B-lymphocytes. Am J Respir Cell Mol 1997, 17(4):414-421.
254. Pabst R., Tschernig T. Lymphocytes in the Lung - an Often Neglected Cell - Numbers, Characterization and Compartmentalization. Anat Embryol 1995, 192(4):293-299.
255. Miossec P. IL-17 and Th17 cells in human inflammatory diseases. Microbes Infect 2009, 11(5):625-630.
256. Aujla S.J., Dubin P.J., Kolls J.K. Interleukin-17 in pulmonary host defense. Exp Lung Res 2007, 33(10):507-518.
257. Kuchroo V., Korn T., Bettelli E., Carrier Y., Gao W., Strom T., et al. Interplay between pathogenic effector Th17 and regulatory T cells in autoimmunity and tissue inflammation. Clin Exp Rheumatol 2008, 26(4):7145.
258. Veldhoen M., Hocking R.J., Atkins C.J., Locksley R.M., Stockinger B. TGF beta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006, 24(2):179-189.
259. Tesmer L.A., Lundy S.K., Sarkar S., Fox D.A. Th17 cells in human disease. Immunol Rev 2008, 223:87-113.
260. Aujla S.J., Chan Y.R., Zheng M.Q., Fei M.J., Askew D.J., Pociask D.A., et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med 2008, 14(3):275-281.
261. Aujla S.J., Kolls J.K. IL-22: A critical mediator in mucosal host defense. J Mol Med Immunol 2009, 87(5):451-454.
262. Dubin P.J., Kolls J.K. IL-17 in Cystic Fibrosis: More Than Just Th17 Cells. Am J Respir Crit Care Med 2011, 184(2):155-157.
263. Dubin P.J., McAllister F., Kolls J.K. Is cystic fibrosis a TH17 disease?. Inflamm Res 2007, 56(6):221-227.
264. Dubin P.J., Kolls J.K. IL-23 mediates inflammatory responses to mucoid Pseudomonas aeruginosa lung infection in mice. Am J Physiol Lung Cell Mol Physiol 2007, 292(2):L519-L528.
265. Dubin P.J., Martz A., Eisenstatt J.R., Fox M.D., Logar A., Kolls J.K. Interleukin-23-Mediated Inflammation in Pseudomonas aeruginosa Pulmonary Infection. Infect Immun 2012, 80(1):398-409.
266. Brodlie M., Lordan J., Ward C. Can cells other than Th17 lymphocytes be important sources of IL-17 in the lungs?. Thorax 2011, 66(12):1096-1097.
267. Brodlie M., McKean M.C., Johnson G.E., Anderson A.E., Hilkens C.M.U., Fisher A.J., et al. Raised interleukin-17 is immunolocalised to neutrophils in cystic fibrosis lung disease. Eur Respir J 2011, 37(6):1378-1385.
268. Decraene A., Willems-Widyastuti A., Kasran A., De Boeck K., Bullens D.M., Dupont L.J. Elevated expression of both mRNA and protein levels of IL-17A in sputum of stable Cystic Fibrosis patients. Respir Res 2010, 10:11.
269. Tan H.L., Regamey N., Brown S., Bush A., Lloyd C.M., Davies J.C. The Th17 Pathway in Cystic Fibrosis Lung Disease. Am J Respir Crit Care Med 2011, 184(2):252-258.
270. Moss R.B. Lymphocytes in cystic fibrosis lung disease: a tale of two immunities. Clin Exp Immunol 2004, 135(3):358-360.
271. Moss R.B., Hsu Y.P., Olds L. Cytokine dysregulation in activated cystic fibrosis (CF) peripheral lymphocytes. Clin Exp Immunol 2000, 120(3):518-525.
272. Conese M. Cystic fibrosis and the innate immune system: therapeutic implications. Endocr Metab Immune Disord Drug Targets 2011, 11(1):8-22.
273. Davies J.C., Johnson M., Booth C., Fidler K., Bush A., Geddes D.M., et al. Age-specific effect of the cystic fibrosis modifier gene, MBL-2. Thorax 2002, 57.
274. Davies J.C., Turner M.W., Klein N., Grp L.M.C.S. Impaired pulmonary status in cystic fibrosis adults with two mutated MBL-2 alleles. Eur Respir J 2004, 24(5):798-804.
275. McDougal K.E., Green D.M., Vanscoy L.L., Fallin M.D., Grow M., Cheng S., et al. Use of a modeling framework to evaluate the effect of a modifier gene (MBL2) on variation in cystic fibrosis. Eur J Hum Genet 2010, 18(6):680-684.
276. Taylor C., Huang B., Dorfman R., Zielenski J., Sandford A., Pare P., et al. The effect of MBL2 gene variants on the age of first infection in Cystic Fibrosis (CF) patients is modified by TGF beta 1 gene variants. Genet Epidemiol 2007, 31(6):646-647.
277. Weersink F.J., Frakking F.N., Brouwer N., Van H.M., Israels J., Nagelkerke A.F., et al. Mannose-binding lectin (MBL) in cystic fibrosis (CF). Pediatr Pulmonol 2007, 271-272.
278. Zielenski J.S., Pereira L., Culpi L., Raskin S., Tsui L.C. Analysis of mannose binding lectin (MBL) haplotyes in a large cohort of cystic fibrosis patients. Am J Hum Genet 2001, 69(4):650-651.
279. Drumm M.L., Konstan M.W., Schluchter M.D., Handler A., Pace R., Zou F., et al. Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med 2005, 353(14):1443-1453.
280. de Faria E.J., de Faria I.C.J., Ribeiro J.D., Ribeiro A.F., Liessel G., Bertuzzo C.S. Association of MBL2, TGF-beta 1 and CD14 gene polymorphisms with lung disease severity in cystic fibrosis. J Bras Pneumol 2009, 35(4):334-342.
281. Gu Y., Harley I.T., Henderson L.B., Aronow B.J., Vietor I., Huber L.A., et al. Identification of IFRD1 as a modifier gene for cystic fibrosis lung disease. Nature 2009, 458(7241):1039-1042.
282. Drumm M.L. Modifier genes and variation in cystic fibrosis. Respir Res 2001, 2(3):125-128.
283. Wright F.A., Strug L.J., Doshi V.K., Commander C.W., Blackman S.M., Sun L., et al. Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. Nat Genet 2011, 43(6):539-546.
284. Banner K.H., De Jonge H., Elborn S., Growcott E., Gulbins E., Konstan M., et al. Highlights of a workshop to discuss targeting inflammation in cystic fibrosis. J Cyst Fibros 2009, 8(1):1-8.
285. Ratjen F.A. Cystic fibrosis: pathogenesis and future treatment strategies. Respir Care 2009, 54(5):595-605.
286. Koehler D.R., Downey G.P., Sweezey N.B., Tanswell A.K., Hu J. Lung inflammation as a therapeutic target in cystic fibrosis. Am J Respir Cell Mol 2004, 31(4):377-381.